Amphotericin B-Induced Nephrotoxicity: A Review

REFERENCES

• Springate J. Amphotericin toxicity. Pediatr Nephrol 1994; 8: 632–640.
   PubMedGoogle Scholar
• Peacock JE, Herrington DA, Cruz JM. Amphotericin B therapy: past, present, and future. Infect Dis Clin Pract 1993; 2: 81–93.
   Web of Science ®Google Scholar
• Khoory BJ, Vino L, Dall'Agnola A, Fanos V. Candida infections in neonates: a review. J Chemother 1999; 11 (5): 367–378.
   Google Scholar
• Schwarz A, Perez-Canto A. Nephrotoxicity of antiinfec-tive drugs. Int J Clin Pharmacol Ther 1998; 36 (3): 164–167.
   PubMedGoogle Scholar
• Wu TC. On the development of antifungal agents: per-spective of the U.S. Food and Drug Administration. Clin Infect Dis 1994; 19 (Suppl 1): S54-58.
   Google Scholar
• Rinaldi MG. Laboratory evaluation of antifungal agents: a brief overview. Clin Infect Dis 1992; 14 (Suppl 1): S130–S3.
   Google Scholar
• Stevens DA. Therapy for opportunistic fungal infections: past, present and future. Indian J Cancer 1995; 32: 1–9.
   PubMedGoogle Scholar
• Espinel-Ingroff A, Shadomy S. In vitro and in vivo evalu-ation of antifungal agents. Eur J Clin Microbiol Infect Dis 1989; 8: 352–61.
   PubMed Web of Science ®Google Scholar
• de Marie S. Liposomal and lipid-based formulations of amphotericin B. Leukemia 1996; 10 (Suppl 2): S93–S6.
   Google Scholar
• Hiemenz JW, Walsh TJ. Lipid formulations of ampho-tericin B: recent progress and future direction. Clin Infect Dis 1996; 22 (Suppl 2): S133–S44.
   Google Scholar
• Hoitsma JA, Wetzels JFM, Koene R. Drug-induced nephrotoxicity. Aetiology, clinical features and management. Drug Safety 1991; 6 (2): 131–147.
   PubMed Web of Science ®Google Scholar
• Kaloyanides GJ. Antibiotic-related nephrotoxicity. Nephrol Dial Transpl 1994; Supplement 4: 130-134
   Google Scholar
• Christiansen KJ, Bernard EM, Gold JW, Armstrong DA. Distribution and activity of amphotericin B in humans. J Infect Dis 1985; 152: 1037–1043.
   PubMed Web of Science ®Google Scholar
• Baley JE, Meyers C, Kliegman RM. Pharmacokinetic outcome and toxic effects of amphotericin B and 5 fluorocyto-sine in neonates. J Pediatr 1990; 116: 791–797.
   PubMed Web of Science ®Google Scholar
• Zager RA, Bredl CR, Schimpf BA. Direct amphotericin B-mediated tubular toxicity: assessment of selected cytoprotec-tive agents. Kidney Intern 1992; 41: 1588–1594.
   PubMed Web of Science ®Google Scholar
• Sawaya B, Briggs J, Schnermann J. Amphotericin B nephrotoxicity: the adverse consequence of altered membrane properties. J Am Soc Nephrol 1995; 6: 156–164.
   Google Scholar
• Brajtburg J, Powderly W, Medoff G. Amphotericin B: current understanding of mechanism of action. Antimicrob Agents Chemother 1990; 34: 183–188.
   PubMed Web of Science ®Google Scholar
• Miller RP, Bates GH. Amphotericin B toxicity. Ann Inter Med 1969; 71: 1089–1092.
   PubMed Web of Science ®Google Scholar
• Sabra R, Takahaski R, Branch A, Badr K. Mechanism of amphotericin B-induced reduction of glomerular filtration rate. J Pharmacol Exp Ther 1990; 253: 34–37.
   PubMed Web of Science ®Google Scholar
• Ford DM. Basic mechanism of aminoglycoside nephro-toxicity. Pediat Nephrol 1994; 8 (5): 635–636.
   Google Scholar
• Butler KM, Rench MA Baker CJ. Amphotericin B as a single agent in the treatment of systemic candidiasis in neonates. Pediatr Infect Dis J 1990; 9: 51–56.
   Google Scholar
• Fisher MA, Talbot GH, Maislin G. Risk factor for amphotericin B-associated nephrotoxicity. Am J Med 1989; 87: 547–552.
   PubMed Web of Science ®Google Scholar
• Richardson MD, Warnock D. Fungal infections. Diagnosis and management. 2nd Edition, Blackwell Science Ltd. 1997: 20-58.
   Google Scholar
• Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid for-mulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998; 27 (3): 603–618.
   PubMed Web of Science ®Google Scholar
• Slain D. Lipid-based amphotericin B for the treatment of fungal infections. Pharmacotherapy 1999; 19 (3): 306–323.
   PubMed Web of Science ®Google Scholar
• Myint H. AmBisome: an overview of current use. Hosp Med 1999; 60 (2): 123–126.
   PubMed Web of Science ®Google Scholar
• Persson U, Tennvall GR, Anderson S, Tyden G, Wettermark B. Cost-effectiveness analysis of treatment with liposomal amphotericin B versus conventional amphotericin B in organ or bone marrow transplant recipients with systemic mycoses. Pharmoeconomics 1992; 2 (6): 500–508.
   PubMedGoogle Scholar
• Nucci M, Loureiro M, Silveira F, et al. Comparison of the toxicity of amphotericin B in 5% dextrose with that of amphotericin B in fat emulsion in a randomized trial with can-cer patients. Antimicrob Agents Chemother 1999; 43 (6): 1445–1448.
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Letscher V, Andres E, Cavalier A. Safety and efficacy of amphotericin B colloidal dispersion. An overview. Chemotherapy 1999; 45 Suppl 1: 67–76.
   PubMedGoogle Scholar
• Gurwith M, Mamelok R, Pietrelli L, Du Mond C. Renal sparing by amphotericin B colloidal dispersion: clinical experi-ence in 572 patients. Chemotherapy 1999; 45 Suppl 1: 39–47.
   PubMedGoogle Scholar
• Linden P, Lee L, Walsh TJ. Retrospective analysis of the dosage of amphotericin B lipid complex for the treatment of invasive fungal infections. Pharmacotherapy 1999; 19 (11): 1261–1268.
   PubMed Web of Science ®Google Scholar
• Cherry JD, Lloyd CA, Quilty JF. Amphotericin B in children. J Pediatr 1969; 75: 1063–1066.
   PubMed Web of Science ®Google Scholar
• Faix RG. Systemic candida infection in infants in inten-sive care nurseries: high incidence of central nervous system involvment J Pediatr 1984; 105: 616–619.
   Google Scholar
• Groll AH, Muller FM, Piscitelli SC, Walsh TJ. Lipid for-mulations of amphotericin B: clinical perspectives for the man-agement of invasive fungal infections in children with cancer. Klin Padiatr 1998; 210 (4): 264–273.
   PubMed Web of Science ®Google Scholar
• Prentice HG, Hann IM, Herbrecht R. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknow origin in neutropenic patients. Br J Haematol 1997; 98: 711–718.
   PubMed Web of Science ®Google Scholar
• Nath CE, Shaw PJ, Gunning R, McLachlan AJ, Earl JW. Amphotericin B in children with malignant disease: a comparison of the toxicities and pharmacokinetics of ampho-tericin B administered in dextrose versus lipid emulsion. Antimicrob Agents Chemother 1999; 43 (6): 1417–1423.
   PubMed Web of Science ®Google Scholar
• Ng PC. Systemic fungal infections in neonates. Arch Dis Child 1994; 71: F130–135.
   Google Scholar
• Al Arishi H, Frayha HH, Kalloghlian A, Al Alaiyan S. Liposomal amphotericin B in neonates with invasive candidia-sis. Am J Perinatol 1998; 15 (11): 643–648.
   PubMed Web of Science ®Google Scholar
• Scarcella A, Pasquariello MB, Giugliano B. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998; 17: 146–148.
   PubMed Web of Science ®Google Scholar
• Weitkamp JH, Poets CF, Sievers R, et al. Candida infection in very low birth-weight infants: outcome and nephrotoxicity of treatment with liposomal amphotericin B (AmBisome). Infection 1998; 26 (1): 11–15.
   PubMedGoogle Scholar
• Friedlich PS, Steinberg I, Fujitani A, deLemos RA. Renal tolerance with the use of intralipid-amphotericin B in low-birth-weight neonates. Am J Perinatol 1997; 14 (7): 377–383.
   Google Scholar
• Albengres E, Le Louet H, Tillement JP. Systemic anti-fungal agents. Drug interactions of clinical significance. Drug Safety 1998; 18 (2): 83–97.
   PubMed Web of Science ®Google Scholar
• Fanos V, Cataldi L. Antibacterial induced nephrotoxici-ty in the newborn. Drug Safety 1999; 20, 3: 245–262.
   PubMed Web of Science ®Google Scholar
• Fanos V, Dall'Agnola A. Antibiotic treatment of infec-tions in neonates: a review. Drugs 1999; 58 (3): 406–427.
   Google Scholar
• Kennedy MS, Deeg HJ, Siegel M. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow trasplantation. Trasplantation 1982; 35: 211–214.
   Web of Science ®Google Scholar
• Fanos V, Khoory BJ. Antimicrobial survey on urinary tract isolated micro-organisms in a pediatric department. J Chemother 1999; 11 (4): 255–259.
   PubMed Web of Science ®Google Scholar
• Mangiarotti P, Pizzini C, Fanos V. Antibiotic prophylax-is in children with relapsing urinary tract infections. J Chemother 2000; 12, 2: 115–123.
   PubMed Web of Science ®Google Scholar
• Hiddemann W, Maschmeyer G, Link H, Helmering M, Adam D. Therapy of infections in patients with acute leukemia. Med Klin 1997; 92 (7): 406–409.
   Google Scholar
• Drouhet E, Dupont B. Evolution of antifungal agents: past, present, and future. Rev Infect Dis 1987; 9(Suppl 1): S4–S14.
   Google Scholar
• Camp MJ, Wingard JR, Gilmore CE, et al. Efficacy of low-dose dopamine in preventing amphotericin B nephrotoxic-ity in bone marrow transplant patients and leukemia patients. Antimicrob Agents Chemother 1998; 42 (12): 3103–3106.
   PubMed Web of Science ®Google Scholar
• Perkins WR, Minchey SR, Boni LT. Amphotericin B-phospholipid interactions responsible for reduced mammalian toxicity. Biochim Biophys Acta 1992; 1107: 271–282.
   PubMed Web of Science ®Google Scholar
• Pizzini C, Mussap M, Plebani M, Fanos V. C-reactive protein and serum amyloid A in neonatal infections. Scand J Infect Dis 2000; 32: 229–235.
   PubMedGoogle Scholar
• Miano-Mason TM. Mechanisms and management of amphotericin B-induced nephrotoxicity. Cancer Pract 1997; 5 (3): 176–181.
   PubMedGoogle Scholar